Pacira BioSciences Inc (NASDAQ: PCRX) on Friday, plunged -3.01% from the previous trading day, before settling in for the closing price of $19.57. Within the past 52 weeks, PCRX’s price has moved between $11.16 and $35.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.46%. The company achieved an average annual earnings per share of 10.31%. With a float of $44.58 million, this company’s outstanding shares have now reached $46.15 million.
Considering the fact that the conglomerate employs 712 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.17%, operating margin of -8.56%, and the pretax margin is -7.9%.
Pacira BioSciences Inc (PCRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Pacira BioSciences Inc is 3.45%, while institutional ownership is 112.54%. The most recent insider transaction that took place on Dec 13 ’24, was worth 9,880. In this transaction Chief Operating Officer of this company sold 500 shares at a rate of $19.76, taking the stock ownership to the 115,200 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Officer proposed sale 500 for $19.76, making the entire transaction worth $9,880.
Pacira BioSciences Inc (PCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.31% per share during the next fiscal year.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Pacira BioSciences Inc (PCRX) is currently performing well based on its current performance indicators. A quick ratio of 1.89 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.22. Likewise, its price to free cash flow for the trailing twelve months is 4.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.05, a number that is poised to hit 0.79 in the next quarter and is forecasted to reach 2.91 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Compared to the last year’s volume of 0.86 million, its volume of 1.2 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.40%. Additionally, its Average True Range was 0.95.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 60.89%, which indicates a significant decrease from 64.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.08% in the past 14 days, which was lower than the 113.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.64, while its 200-day Moving Average is $21.70. Nevertheless, the first resistance level for the watch stands at $19.61 in the near term. At $20.24, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.68. If the price goes on to break the first support level at $18.54, it is likely to go to the next support level at $18.10. Now, if the price goes above the second support level, the third support stands at $17.47.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
Market capitalization of the company is 849.95 million based on 46,173K outstanding shares. Right now, sales total 674,980 K and income totals 41,960 K. The company made 168,570 K in profit during its latest quarter, and -143,470 K in sales during its previous quarter.
